How to buy Recursion Pharmaceuticals stock (Recursion Pharmaceuticals)

Recursion Pharmaceuticals is a biotechnology business based in the US. Recursion Pharmaceuticals shares (RXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.03 – a decrease of 18.95% over the previous week. Recursion Pharmaceuticals employs 500 staff and has a trailing 12-month revenue of around $65.2 million.

Our top picks for where to buy Recursion Pharmaceuticals stock

Buy Recursion Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Recursion Pharmaceuticals stock price (NASDAQ: RXRX)

Use our graph to track the performance of RXRX stocks over time.

Recursion Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$6.03
52-week range	$5.60 - $15.74
50-day moving average more info button	$6.77
200-day moving average more info button	$7.86
Wall St. target price	$9.86
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.54

Is it a good time to buy Recursion Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Recursion Pharmaceuticals price performance over time

Historical closes compared with the close of $6.03 from 2024-12-20

1 week (2024-12-16)	-18.95%
1 month (2024-11-22)	5.79%
3 months (2024-09-23)	-9.60%
6 months (2024-06-21)	-31.86%

1 year (2023-12-22)	-41.57%
2 years (2022-12-23)	-19.71%
3 years (2021-12-23)	16.78
5 years (2019-12-19)	N/A

Recursion Pharmaceuticals financials

Revenue TTM	$65.2 million
Gross profit TTM	$-164,128,000
Return on assets TTM	-36.4%
Return on equity TTM	-78.49%
Profit margin	0%
Book value	$1.83
Market Capitalization more info button	$2.4 billion

TTM: trailing 12 months

Recursion Pharmaceuticals share dividends

We're not expecting Recursion Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

Recursion Pharmaceuticals share price volatility

Over the last 12 months, Recursion Pharmaceuticals's shares have ranged in value from as little as $5.6 up to $15.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recursion Pharmaceuticals's is 0.802. This would suggest that Recursion Pharmaceuticals's shares are less volatile than average (for this exchange).

To put Recursion Pharmaceuticals's beta into context you can compare it against those of similar companies.

• NGM Biopharmaceuticals (NGM.US): 1.261
• Lixte Biotechnology (LIXT.US): -0.172
• Ultragenyx (RARE.US): 0.581

Recursion Pharmaceuticals overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Frequently asked questions

null
What percentage of Recursion Pharmaceuticals is owned by insiders or institutions?
Currently 3.457% of Recursion Pharmaceuticals shares are held by insiders and 69.388% by institutions. How many people work for Recursion Pharmaceuticals?
Latest data suggests 500 work at Recursion Pharmaceuticals. When does the fiscal year end for Recursion Pharmaceuticals?
Recursion Pharmaceuticals's fiscal year ends in December. Where is Recursion Pharmaceuticals based?
Recursion Pharmaceuticals's address is: 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101 What is Recursion Pharmaceuticals's ISIN number?
Recursion Pharmaceuticals's international securities identification number is: US75629V1044